thiophenes has been researched along with afuresertib in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 5 (38.46) | 2.80 |
| Authors | Studies |
|---|---|
| Brigandi, RA; Chen, C; Gauvin, J; Harrison, SJ; Kumar, R; Morris, SR; Opalinska, JB; Smith, DA; Spencer, A; Yoon, SS | 1 |
| Leleu, X | 1 |
| Aktan, G; Allred, AJ; Becerra, CR; Cornfeld, M; Ferron-Brady, G; Gauvin, J; Ibrahim, N; Motwani, M; Orford, K; Papadopoulos, KP; Patnaik, A; Rasco, DW; Tolcher, AW | 1 |
| Allen, CE; Arceci, RJ; Cornfeld, M; Dunkel, IJ; Heaney, ML; Jacobsen, E; McClain, K; Morris, SR; Murnane, A; Noble, R; Portnoy, A; Reedy, BA; Rodriguez-Galindo, C; Smith, DA; Vaiselbuh, S; Vassallo, R; Whitlock, J | 1 |
| Haniuda, M; Hosokawa, Y; Hyodo, T; Karnan, S; Konishi, H; Ota, A; Tsuzuki, S; Wahiduzzaman, M; Yamaji, M | 1 |
| Aleem, E; Arceci, RJ; Azorsa, DO; Bista, R; Henry, MM; Lee, DW; Patel, AR; Wai, DH | 1 |
| Chen, CI; Johnston, JB; Kakar, S; Lau, A; Le, LW; Levina, O; Paul, H; Queau, M; Smith, DA; Snitzler, S; Trudel, S; Wang, T; Wei, EN | 1 |
| Blagden, SP; DeSilvio, M; Frangou, E; Gabra, H; Goh, JC; Gopalakrishna, P; Hall, M; Hamilton, AL; Lisyanskaya, AS; Meniawy, TM; Michael, A; Mileshkin, L; Stronach, EA; Wong, S | 1 |
| Bowen, JP; Güner, OF; Matesic, DF; Uko, NE | 1 |
| Hanamura, I; Hosokawa, Y; Hyodo, T; Kanasugi, J; Karnan, S; Konishi, H; Lam, VQ; Mizuno, S; Ota, A; Rahman, ML; Takami, A; Tsuzuki, S; Wahiduzzaman, M | 1 |
| Chen, X; Cheng, S; Dai, X; Ding, L; Guo, H; Guo, Q; Wang, J; Wang, T; Xu, X; Zhang, W | 1 |
| Doan, HQ; Limmer, AL; Narayanan, D; Rady, PL; Simonette, RA; Tyring, SK; Wu, JH | 1 |
| Liang, F; Min, B; Wang, CX; Wang, F; Wang, Y; Yang, Z | 1 |
1 review(s) available for thiophenes and afuresertib
| Article | Year |
|---|---|
Akt Pathway Inhibitors.
Topics: Antineoplastic Agents; Benzylamines; Cell Line, Tumor; Diamines; Drug Design; Heterocyclic Compounds, 3-Ring; Humans; Molecular Docking Simulation; Phosphatidylinositol 3-Kinases; Phospholipids; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Signal Transduction; Structure-Activity Relationship; Sulfonamides; Thiadiazoles; Thiophenes | 2020 |
5 trial(s) available for thiophenes and afuresertib
| Article | Year |
|---|---|
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Patient Safety; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Thiophenes; Time Factors; Young Adult | 2014 |
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Early Termination of Clinical Trials; Female; Humans; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Multiple Myeloma; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridones; Pyrimidinones; Thiophenes; Tumor Burden | 2015 |
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.
Topics: Adult; Aged; Antineoplastic Agents; Female; Hematologic Neoplasms; Histiocytosis, Langerhans-Cell; Humans; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrazoles; Thiophenes; Treatment Outcome; United States | 2017 |
A phase 2 study of ofatumumab (Arzerra
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Progression-Free Survival; Proto-Oncogene Proteins c-akt; Pyrazoles; Remission Induction; Thiophenes | 2019 |
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Monitoring; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Recurrence; Thiophenes; Treatment Outcome | 2019 |
7 other study(ies) available for thiophenes and afuresertib
| Article | Year |
|---|---|
A key to the quest?
Topics: Female; Humans; Male; Multiple Myeloma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Thiophenes | 2014 |
Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzylamines; Caspase 3; Caspase 7; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Forkhead Box Protein O1; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Inhibitory Concentration 50; Mesothelioma; Oxadiazoles; Phosphorylation; Phosphorylcholine; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinoxalines; Sulfonamides; Thiadiazoles; Thiophenes | 2017 |
Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.
Topics: Adolescent; Adrenal Cortex Hormones; Butadienes; Combined Modality Therapy; Cytarabine; Disease Progression; Drug Resistance; Drug Therapy, Combination; Enzyme Activation; Exons; HEK293 Cells; Hematopoietic Stem Cell Transplantation; Histiocytosis, Langerhans-Cell; Humans; Male; MAP Kinase Kinase 1; MAP Kinase Signaling System; Molecular Targeted Therapy; Mutation; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazoles; Pyridones; Pyrimidinones; Recombinant Fusion Proteins; Sequence Deletion; Thiophenes; Vincristine | 2018 |
Biallelic loss of FAM46C triggers tumor growth with concomitant activation of Akt signaling in multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Bortezomib; Carcinogenesis; Cell Cycle; Cell Line, Tumor; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Mice; Mice, SCID; Multiple Myeloma; Nucleotidyltransferases; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazoles; Signal Transduction; Thiophenes | 2020 |
Ceritinib increases sensitivity of AKT inhibitors to gastric cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Glycogen Synthase Kinase 3 beta; Humans; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Stomach Neoplasms; Sulfones; Thiophenes; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL-1 cell growth.
Topics: Antineoplastic Agents; Carcinoma, Merkel Cell; Cell Line, Tumor; Cell Proliferation; Genes, p16; Glycogen Synthase Kinase 3; Humans; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Signal Transduction; Skin Neoplasms; Thiophenes; TOR Serine-Threonine Kinases; Trans-Activators; Up-Regulation | 2021 |
The Protective Mechanism of Afuresertib against Esophageal Cancer.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Esophageal Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Rats; Thiophenes | 2022 |